Abstract The use of proteomic approaches in investigating diseases is continuing to expand and has started to provide answers to substantial gaps in our understanding of disease pathogenesis as well as in the development of effective strategies for the early diagnosis and treatment of diseases. Biophysical techniques form a crucial part of the advanced proteomic techniques currently used and include mass spectrometry and protein separation techniques, such as twodimensional gel electrophoresis and liquid chromatography. The application of biophysical proteomic techniques in the study of disease includes delineation of altered protein expression, not only at the whole-cell or tissue levels, but also in subcellular structures, protein complexes, and biological fluids. These techniques are also being used for the discovery of novel disease biomarkers, exploration of the pathogenesis of diseases, development of new diagnostic methodologies, and identification of new targets for therapeutics. Proteomic techniques also have the potential for accelerating drug development through more effective strategies for evaluating a specific drug's therapeutic effects and toxicity. This article discusses the application of biophysical proteomic techniques in delineating cardiovascular disease and other diseases, as well as the limitations and future research directions required for these techniques to gain greater acceptance and have a larger impact.
Introduction
Some of the greatest discoveries in medicine are correlated with advances in biophysical techniques. Developments in microscopy made it possible to view bacteria, and the discovery of X-rays promoted tremendous progress in medical practice (Egerton 1967; Gottfried 1997) . In recent years, many novel techniques have been developed to investigate the structure, properties, and biological functions of proteins. The application of these techniques allows researchers to be able to monitor how the structure and dynamics of proteins enable specific biological functions (Yates et al. 2009; Katan and Dekker 2011; Razgulin et al. 2011) . The development of modern biophysical techniques in turn has allowed researchers to utilize these techniques in the study of diseases (Dammer et al. 2011; Schiffer et al. 2011) . Among the different biophysical techniques, proteomic approaches are the most promising in disease investigations. The term "proteomics" was first suggested in 1997 (James 1997) as an analogy with genomics (the study of genes). Proteomics is the large-scale investigation of proteins. Biophysical proteomic techniques mainly focus on protein separation techniques, including two-dimensional gel electrophoresis (2DE) and liquid chromatography (LC), and protein characterization techniques, such as mass spectrometry (MS). The greatest advance in biophysical proteomic techniques over the last decade has been in MS (Yates et al. 2009 ). Mass spectrometers are used both in academia and industry for routine and research purposes. While they are mostly used in academia for the analysis of proteins and peptides, MS has proven to be important in numerous other clinical and non-clinical applications. The most common clinical uses of mass spectrometers include hemoglobin analysis (Kleinert et al. 2008) , drug testing (Botre 2008) and neonatal screening (Schulze et al. 2003) . Non-clinical uses of mass spectrometers include the determination of oil composition and water quality (Jeannot et al. 2000) . Our purpose in this review is to describe standard biophysical proteomic approaches, discuss technological advances utilized in recent proteomic studies, and show how proteomic approaches are applied to gain insight into complex disease states.
Biophysical proteomic techniques

Liquid chromatography
An important aspect of proteomics involves proper protein separation for subsequent analysis, and LC is currently the method of choice for sample preparation and pre-MS analysis involving protein separation. LC is a form of chromatography that utilizes liquid as the mobile phase for protein separation and either a solid or a liquid on a solid support as the stationary phase. High-performance LC (also referred to as high-pressure liquid chromatography, HPLC) is the most common type of LC used in proteomic applications. HPLC is used to separate compounds into less complex fractions, often allowing the identification, quantification, and purification of the individual components of the mixture. The most important components of a HPLC system include a pump to provide the pressure required to move the mobile phase and analyte through the packed column, a stationary phase which separates the analytes, and a detector of the separated analyte. Analyte detection depends on the strength of the interactions of the analyte with the stationary phase, the composition of solvent(s) used, and the flow rate of the mobile phase. While LC has not experienced the same jump in improvements as MS, some of its recent advances are resulting in its increased use. Examples include ultra highpressure LC (UHPLC) (Jorgenson 2010) and capillary electrochromatography (Breadmore et al. 2011) , which increase separation speed as well as improve the sensitivity and resolution of proteins detected in subsequent steps. Other pre-fractionation techniques, including differential centrifugation (de Araujo et al. 2008) , affinity chromatography (Selvaraju and El Rassi 2011) , and free flow electrophoresis (Drews et al. 2007 ), can also be used to expand the dynamic depth of proteome analysis by resolving proteins present in low concentrations or with extreme biophysical properties.
Mass spectrometry
The most common approach for analyzing proteins is mass spectrometry. This biophysical technique separates and identifies different molecules by measuring the mass to charge (m/z) ratio of charged particles. The MS instruments consist of an ion source, a mass analyzer, and a detector. The ion source splits the sample into ions, while the mass analyser sorts the ions according to their masses by applying electromagnetic fields. The detector measures the value of an indicator quantity, thereby allowing for the calculation of the abundances of each ion present (Fig. 1) . Different methods are utilized to split the sample into ions. Electrontransfer dissociation (ETD) is a method of fragmenting cations by transferring electrons derived from radical anions to the cations (Eq. 1) for tandem mass spectrometric analysis (MS/MS; Zhou et al. 2011 , are often observed when peptides or proteins are fragmented by ETD. Equation 1 shows the formula which governs how ETD induces the fragmentation of peptides or proteins:
where [M+nH] n+ is the multiply charged positive ion, and A is the anion.
ETD was developed and used for peptide analysis in quadrupole linear ion trap (QLT) by the Hunt group in 2004 (Syka et al. 2004; Coon et al. 2005) . Because the protonated peptides are induced for fragmentation along Fig. 1 Schematic of tandem mass spectrometry (MS1, MS2). Mass spectrometers consist of three main components: an ion source, mass filters and detectors. MALDI, Matrixassisted laser desorption/ionization. ESI, electrospray. EI, electron impact the peptide backbone in a sequence-independent manner, ETD leaves labile modifications linked to the peptide chain (such as phosphorylation sites), which allows straightforward identification of the peptide sequence and the site of modification (Chi et al. 2007; Molina et al. 2007; Wang et al. 2010) . However, the resultant ions of the peptide fragmentation are dominated by type c and z ions (Fig. 2) . The fragmentation efficiency of peptides using ETD is lower than that using collision-induced dissociation (CID) or electron-capture dissociation (ECD), which results in fewer peptides being identified. Therefore, ETD is often used in combination with CID. Despite some efforts to improve the fragmentation efficiency of peptide ions, ETD is still challenging, and because ETD is a relatively new method and only used in a few specific types of MS, it has not been widely used in many proteomic applications.
MS instruments also make use of different ion sources and have features that make each instrument advantageous for certain types of analysis. The Fourier transform ion cyclotron resonance (FT-ICR) MS uses a cyclotron to excite ions trapped in a magnetic field. The resulting signal is detected as an image current and offers higher precision and resolution than other methods (Raczynska et al. 2007 ). The more commonly used time-of-flight (TOF) mass analyzers use an electric field to accelerate ions and then measure the time required for them to reach the detector. The trajectories of charged particles are altered according to their mass and charge. Quadrupole analyzers use oscillating electrical fields to selectively stabilize or destabilize the paths of ions.
Two-dimensional gel electrophoresis
A second common approach for proteomic analysis of protein mixtures is 2D differential in gel electrophoresis (2D-DIGE). One advantage of 2D-DIGE is its application for sensitive analytical separations, which can be used to detect differences in protein amounts (Friedman et al. 2009; Minden et al. 2009; Brewis and Brennan 2010) . In addition, 2D-DIGE can be used as a pre-fractionation technique for subsequent protein quantification and is described in more detail in the quantitative proteomics section.
Quantitative proteomic methods
Many biophysical proteomic investigations involve the quantitation of proteins or peptides in the sample being analyzed. Quantitative proteomics has significantly advanced in the last decade. In 2D-DIGE, protein samples are labeled on lysine residues with up to three distinct fluorescent dyes, known as CyDye DIGE fluors (Cy2, Cy3 and Cy5). These CyDye-labeled proteins are mixed prior to separation on the same 2DE gel. Because these fluorescent dyes also have different excitation wavelengths, it is possible to visualize and separate proteins from different samples after 2DE (Fig. 3) . Due to the wide dynamic range (3.6 orders of magnitude) of these dyes, 2D-DIGE has increased the linearity and sensitivity of 2DE, making it a highly reliable quantitative technique. The sensitivity of the fluor minimal CyDyes range from 0.025 to 0.075 ng, while the CyDye fluor saturation dyes are even more sensitive, with sensitivities as low as 15 pg. The most sensitive general stain used for 2DE is silver staining, which has a sensitivity of 1 ng. The main disadvantage of this popular method is that some proteins do not contain lysine residues and would not be labeled or quantified.
Label-free methods, where quantification relies on spectral counting or the comparison of intensity/time profiles of precursor ions across multiple LC runs, is also becoming popular. Other quantitative methods involve the incorporation of stable isotopes or isobaric tags, which allows for absolute quantification (AQUA; Gerber et al. 2003) , stable isotope labeling with amino acids in cell culture (SILAC; Ong et al. 2002) , as well as the chemical labeling of proteins with isotope-coded affinity tags (ICAT; Gygi et al. 1999) . However, the best results for the analysis of multiple samples are achieved (highest number of identified proteins and peptides) by using iTRAQ (isobaric tags for relative and absolute quantitation) for up to four samples (4-plex), followed by tandem mass tags (TMT; Thompson et al. 2003) 6-plex and then iTRAQ 8-plex (Pichler et al. 2010) . Some chemical labeling methods, such as ICAT, may lead to lower numbers of identified peptides in comparison to other quantitative methods, such as iTRAQ (Wu et al. 2006) .
Chemical derivatization of peptides with different channels of the same isobaric tag leads to a simple MS peak containing modified peptides with very similar or identical mass, and these peptides can be further resolved using MS/ MS analysis. Quantification is based on the relative intensities of known reporter ions in the low-mass range of MS/MS Fig. 2 Peptide fragmentation notation. Notation based upon the nomenclature proposed by Roepstorff and Fohlman (1984) . Collisioninduced dissociation cleaves the amide bonds along the backbone and gives rise to a-, b-and y-type product ions. In electron-capture dissociation (ECD) and electron-transfer dissociation (ETD) processes, the major fragmentation process is the cleavage of the nitrogen-alpha carbon (N-C α ) bonds along the peptide backbone to give rise to complementary c-and z-type fragment ions spectra (Figs. 4, 5) . Two scans are typically acquired for each precursor analyzed using a LTQ Orbitrap (Thermo Fisher Scientific, Waltham, MA), which consists of a CID scan for identification and a HCD (higher energy collisional dissociation) scan for quantification (Kocher et al. 2009; Dayon et al. 2010 ). The orbitrap is one of the most commonly used mass spectrometer for shotgun proteomics and is fast becoming one of the most popular types of mass spectrometer for quantitation using label-free or isobaric tags.
Selected Reaction Monitoring (SRM) is a newer method for MS quantification that is very sensitive and has a lower limit of detection in the subfemtomolar range (Addona et al. 2011) , as well as a linear quantitative range of four to five orders of magnitude for peptides (Picotti et al. 2009 ). SRM Quantification of six samples (6-plex) using isobaric tags for relative and absolute quantitation (iTRAQ). After reduction of disulfide bonds using Tris[2-carboxyethyl] phosphine (TCEP) solution and alkylation of cysteine residues using s-methylmethanethiosulfonate (MMTS), proteins are trypsin-digested, individually iTRAQ labeled, mixed together and then analyzed by liquid chromatography-tandem MS (LC-MS/MS). A database search of the fragmentation data is used to identify the labeled peptides and hence the corresponding proteins. The fragmentation of the attached tag gives a low-molecular mass reporter ion that is used to relatively quantify the peptides as well as identify the proteins from which the peptides originated. Con Control group sample, Exp experimental group sample plots are simple to interpret, making this method excellent for specific quantitation. In SRM, the first MS analyzer allows only a single mass through as the user specifies the parent mass of the molecule for MS/MS fragmentation. This first selection is important as it allows the fragment ion of interest to be monitored and quantified in the presence of complex samples. The second MS analyzer monitors for a single or multiple user-defined fragment ions.
The power of SRM has been exemplified by the Pawson group that used affinity purification-SRM (AP-SRM) to quantitatively investigate the changes in protein interactions with growth factor receptor-bound protein 2 (GRB2) (Bisson et al. 2011) . GRB2 is a widely expressed adaptor protein involved in several signal transduction pathways. A SH2 domain on GRB2 binds to phosphorylated tyrosine-containing peptides on receptors, such as the epidermal growth factor (EGF) receptor tyrosine kinase, leading to the activation of other proteins and their downstream kinases. Using HEK293T cells with stable FLAG-tagged GRB2 protein expression, these researchers identified 108 GRB2-associated proteins after exposing the cells to the tyrosine phosphatase inhibitor pervanadate, followed by affinity purification of the FLAG-tagged GRB2 protein and LC-MS/MS. A GRB2 interaction network was then identified with AP-SRM, which utilized information from these 108 GRB2-associated proteins (Bisson et al. 2011 ). The AP-SRM approach reproducibly measured 90 of the 108 GRB2-associated proteins. Subsequent analysis of EGF stimulated HEK293T cells also produced a quantitative temporal profile and identified unique changes in this signaling network (e.g. rapidly bound and rapidly dissociated proteins associated with GRB2). Such an integrative approach utilizing SRM and LC-MS/MS laid the foundation for high-throughput screening of the protein interactions produced by a number of growth factors in a variety of basal and stimulated cells.
Application of biophysical proteomic methods to disease states
Biophysical proteomic methods are utilized by many researchers to investigate different diseased states. A key advantage of proteomic-based studies is the potential for this unbiased approach to discover proteins that are differentially regulated during disease. Some of these differentially regulated proteins may serve as novel biomarkers of disease states and could be used for early detection. Sample preparation is a vital factor for obtaining optimal results for biomarker discovery. The use of several biophysical techniques targeting the proteome that are used in studies is highlighted in Table 1 as well as in the following sections on diseases associated with high economic and social costs.
Cardiovascular disease
Numerous proteomic-based studies have been carried out to investigate and identify protein expression patterns during myocardial ischemia, dilated cardiomyopathy, hypertrophic cardiomyopathy, acute coronary syndrome, and heart failure (Chugh et al. 2010; Cui et al. 2011 ). Many of these proteomic-based studies utilize two main techniques, 2DE and LC-MS/MS. The popularity of 2DE has led to the generation of several online 2D gel-derived databases of human cardiac proteins, including HSC-2DPAGE (Evans et al. 1997) , HEART-2DPAGE (Pleissner et al. 1996) , and HP-2DPAGE (Appel et al. 1996; Muller et al. 1996) .
In clinical practice, the abundance of certain serum biomarkers, such as troponin I and troponin T, are correlated with the severity of infarction. Testing and validation of new In two recent studies aimed at identifying protein biomarkers for cardiovascular disease (Jaffe et al. 2008; Addona et al. 2011) , candidate biomarkers of extensively fractionated samples were identified by LC-MS/MS and then verified by quantification with multiple reaction monitoring (MRM)-MS and immunoassays. In one of these studies, blood was collected from patients before and during a planned myocardial infarction (PMI;, used therapeutically for treatment of hypertrophic cardiomyopathy) and >100 potentially novel differentially expressed proteins were found after the PMI (Addona et al. 2011) . Some of the differentially expressed proteins are known clinical markers currently utilized for cardiovascular disease (CVD) diagnosis. In another study, differentially expressed tissue proteins detected in a discovery proteomic analysis were analytically quantified in peripheral blood using accurate inclusion mass screening (AIMS) (Jaffe et al. 2008) . AIMS monitors masses previously identified in tissue with an LC-MS/MS approach, such as Orbitrap-MS, and then incorporates these proteins into a software inclusion list for sequence confirmation of a potential biomarker. Both charge state and accurate mass are required for positive candidate identification. An advantage of AIMS is its ability to determine false positive candidates and/or markers present below the detection limit. This resolution allows for high-throughput identification and the ability to focus on an optimal pool of potential candidates. As a result, AIMS is at least fourfold more efficient at identifying peptides of interest than undirected LC-MS/MS experiments. The peptide precursors and fragment ions generated by AIMS are used to configure subsequent MRM-MS experiments. Further verification of quantified differentially expressed proteins in peripheral plasma from patients with PMI or spontaneous MI and controls by MRM-MS or immunoassay suggests that the potential biomarkers (such as tropomyosin 1) are specific for MI. This investigation utilized three different MS approaches to obtain a subset of high confidence markers that may be of potential importance clinically.
Cancer
The application of biophysical proteomic techniques in cancer research ranges from the investigation of disease pathogenesis and exploration of cancer biomarkers to drug-target discovery. A major goal for these applications is to identify proteins specific to a particular type of cancer. One approach worth noting in cancer research is the recent use of ultraviolet and infrared laser desorption ionization (LDI)-MS to identify proteins expressed in cancer tissue (Schafer et al. 2011) . Quantitative mass spectrometry using iTRAQ labeling, separation by strong cation exchange chromatography, and MS by nanoLC/MS/MS (QStar XL MS; Applied Biosystems, Foster City, CA) were used to identify 118 differentially expressed proteins from 16 colorectal cancer (CRC) tumors (compared to patient-paired adjacent normal mucosa) (Johnson et al. 2006) . The differentially expressed proteins accounted for less than 9% of the total number of proteins identified and quantified. Proteins involved in glycolysis, calcium binding and protease inhibition were increased in CRC tumors, while proteins associated with a loss of ATP production were reduced. Validation of the iTRAQ data by immunoblotting and immunohistochemistry showed a strong correlation between this cancer and the identified proteins, regardless of the method (Johnson et al. 2006) .
High-throughput approaches also can be used for biomarker studies. Whiteaker et al. (2011) evaluated plasma samples from 80 patients using SRM-MS. They then developed 88 quantitative assays based on a subset of prioritized candidates previously identified in a mouse model of breast cancer. The biomarker candidate prioritization was done using AIMS and semi-quantitative (SQ)-SRM. Only those candidates detected in plasma by AIMS were then further analyzed by specific assays. In SQ-SRM, signals from proteins in the plasma with the same abundance in tumorbearing and control animals (housekeeping proteins) were used to normalize SRM signals across different SRM-MS runs. Quantitative SRM-MS showed that a total of 36 proteins were elevated in the plasma of tumor-bearing animals (Whiteaker et al. 2011) . The high cost prevents the development of quantitative SRM for all candidates, whereas SQ-SRM is more cost effective.
Multiple adaptations also have been incorporated into a single study to better identify signaling pathways and targets. For example, the phosphoproteome of androgen-repressed cancer of human prostate cells was investigated using three enrichment strategies-calcium phosphate precipitation (CPP), immobilized metal ion affinity chromatography (IMAC), and TiO 2 -modified metal oxide chromatography. After enrichment, MS/MS was performed on a hybrid linear trap quadrupole (LTQ)/FT-ICR mass spectrometer, identifying 385 phosphoproteins (Wales and Engen 2006) . These results suggest the involvement of key signal transduction pathways in this prostate cancer cell line, including the mammalian target of rapamycin (mTOR) pathway and the E2F signaling pathway. Based on their results, the authors suggested that a possible mechanism for the androgen-repressed cancer cell line may be related to the detection of phosphorylated androgen-induced proliferation inhibitor in this cell line (Wales and Engen 2006 ).
Alzheimer's disease and other neurodegenerative conditions Biophysical proteomic studies are making significant contributions to our understanding of the components of pathological brain lesions found in patients with Alzheimer's disease (AD). AD is the seventh leading cause of death in the USA, and its mortality rate has increased by 46.1% between 2000 and 2006 (Alzheimer's Association 2010). Quantitative phosphoproteomic analysis of neuronal intermediate filament proteins from AD patients using iTRAQ showed 13 hyperphosphorylated sites in the AD brain compared to the control brain (Rudrabhatla et al. 2010) . These results strongly suggest that aberrant hyperphosphorylation of neuronal intermediate filament proteins are involved in AD. The identification of biomarkers that can detect AD in its early stages are important as treatment would be most effective during the preclinical stage (Skorobogatko et al. 2011) . AD-associated changes in cerebrospinal fluid (CSF) were measured using 2D-DIGE and LC-MS/MS. Cohorts with very mild and mild AD-type dementia showed higher YKL-40 protein levels than control subjects (Craig-Schapiro et al. 2010 ). The CSF YKL-40/Aβ42 ratio was able to predict the risk of developing cognitive impairment with the same accuracy as the best CSF biomarkers identified to date, namely, tau/Aβ42 and p-tau 181/ Aβ42. As such, YKL-40 together with Aβ42 are likely to have potential prognostic utility as a biomarker for preclinical AD. However, the limited availability of human samples containing a rich source of potential new biomarkers for diagnosing neurodegenerative disorders has slowed the progression of biomarker discovery in this area of investigation (D'Aguanno et al. 2007 ). Importantly, advances in technologies will allow for proteomics to play an increasing role in identifying biomarkers for early diagnosis, disease progression and therapeutic efficacy.
Renal disease and metabolic diseases
Mass spectrometry-based methods have been widely used for the discovery of potential disease biomarkers for a number of renal diseases, including diabetic glomerulopathy (Merchant and Klein 2010) , acute renal injury (Bennett and Devarajan 2011) , Fanconi syndrome of various causes (Vilasi and Capasso 2010) , and immunoglobulin A nephropathy (Moon et al. 2011) . In general, MS applications in nephrology and urology represent relatively early stages of the discovery process and are likely to herald future progress as specific biomarker candidates are further validated. A capillary electrophoresis (CE)-MS approach can distinguish three pathologically different forms of idiopathic glomerular disease (minimal change disease, membranous nephropathy and focal segmental glomerulosclerosis) based on the pattern of small proteins and peptides in the urine (Weissinger et al. 2004) . Several surface-enhanced laser desorption/ ionization (SELDI)-TOF-MS studies have also shown distinct MS peaks associated with acute rejection (O'Riordan et al. 2004; Schaub et al. 2004) . Some of these peaks were later identified using microcapillary LC-matrix-assisted laser desorption/ionization (MALDI)-MS/MS as proteolytic products of 2-microglobulin, which may be reflective of damaged renal proximal tubule cells (Schaub et al. 2005) . Proteomic analysis by CE-MS was used to compare the urinary polypeptide profiles in acute rejection with control transplant patients without rejection (Wittke et al. 2005) . The distinct urinary polypeptide pattern obtained by CE-MS allowed the identification of 16 of 17 cases of acute tubulointerstitial rejection (Wittke et al. 2005) .
Future prospects
An ongoing problem in the application of proteomics for understanding human diseases is the need for a sensitive and easy-to-use pre-fractionation approach to prepare proteins in complex samples. Single-run analysis on high-resolution columns would simplify many proteomic studies and eliminate the need for pre-fractionation. Matthias Mann's group recently showed that long LC runs (on columns of 50 cm length and 75 μm inner diameter with 1.8-μm C18 beads) with high resolution coupled to an LTQ-Orbitrap Velos instrument (Thermo Scientific) were capable of giving deep and highly sensitive (down to low attomole range) proteome coverage without pre-fractionation (Thakur et al. 2011 ). High-accuracy MS machines, such as the LTQ-Orbitrap Velos and the FT-ICR mass spectrometer, have higher resolution and precision than most other MS machines. These high-accuracy MS machines place less pre-fractionation requirements on samples and will become more common in proteomic laboratories as the cost of these machines continue to decrease.
Proteomics also can be coupled with other biophysical techniques to probe protein interactions and gain insight into protein conformational dynamics, folding and binding studies of mutant proteins associated with important diseases. For example, an increasing number of studies are utilizing hydrogen/deuterium exchange (HDX) coupled to MS to gain an understanding of protein-protein interactions (Englander 2006; Wales and Engen 2006) . In addition, recent rapid technological advancements have made ESI-MS a powerful tool. ESI-MS has advantages over nuclear magnetic resonance and other techniques as it can distinguish between inter-and intramolecular events.
Another biophysical technique with great promise is imaging mass spectrometry (IMS), which allows direct visualization of the distribution of proteins, peptides, metabolites, surface lipids, drugs, trace metals or other small molecules from complex biological tissues in two dimensions. The imaging result provides two kinds of information, namely, the intensity and spatial distribution of the target chemicals, which results in IMS obtaining two-dimensional information from the target samples. The samples vary from biopsy, organ or tissue section to single cell for IMS. There are three main ionization methods for IMS, including secondary ion mass spectrometry (SIMS), MALDI and desorption electrospray ionization (DESI). Despite the development of different IMS approaches, MALDI is still the most popularly used tool for IMS. Many types of cancers have been investigated by IMS using MALDI. This technique shows differences in protein expression from different regions of tumors, including human prostate cancer (Johnson et al. 2006) , human metastasis to the brain (Schwamborn et al. 2007 ) and tumor margins in human renal carcinoma (Oppenheimer et al. 2010 ). The IMS technique has shown great potential in clinical and preclinical applications for the diagnosis, treatment and prognosis, and will become a more popular proteomic technique for investigating diseases.
Conclusion
The availability and significant improvements in proteomic technologies are changing the way we study disease. The size and cost of mass spectrometers continue to decrease and will eventually become commonplace as a standard analytical tool used in a manner similar to immunoassays in clinical use. Biophysical proteomic approaches have added new dimensions to the analysis of clinically relevant samples and promise to revolutionize the way diseases will be diagnosed and treated in the future. In some cases, the use of LC-MS assays are able to give higher sensitivity and specificity while requiring smaller sample volumes (which is important for samples from pediatric patients) than the clinical methods currently used. Quantification of proteins by LC-MS/ MS will continue to improve with better MS machines, software and separation techniques. The ability to automate LC-MS/MS runs will be particularly useful for clinical laboratories, and current work on improving multiplexed assays using LC-MS/MS will reduce the cost of individual assays. However, there are still many challenges to be met regarding the application of proteomic technologies. The complete characterization of any proteome, either qualitatively or quantitatively, is still extremely demanding. The complexity of proteins is increased by the extreme diversity of post-translational modifications as well as single nucleotide polymorphisms. The dynamic range of proteins in samples includes a large number of low-abundance proteins which tests the limits of the best mass spectrometers. A remaining limitation of many proteomic studies is that the statistical design of these investigations is often not adequate for the complex multivariate analysis. The successful transformation of the numerous potential biomarkers discovered by proteomic techniques into routine clinical use will require significant collaboration between researchers, industry, regulatory agencies and clinician laboratories.
